Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies
Gothenburg, April 4, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced the publication of a scientific article describing the mechanism-of-action of Elicera’s universal CAR T-cell enhancement technology platform iTANK in Nature Biomedical Engineering, one of the highest ranked scientific journals in the world. Proof-of-concept data presented in the publication also indicate that the iTANK-platform is universally